Characterizing phenotypes of acute heart failure
Official title: Characterisation of phenotYpes in aCute Heart faiLure patiEnts
Run by Universitätsklinikum Hamburg-Eppendorf · NCT07508891 · Data updated 2026-11-12
This project will try to see if heart function measures, imaging features (radiomics), and blood biomarkers can predict outcomes for adults hospitalized with acute heart failure, including cardiogenic shock.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | Universitätsklinikum Hamburg-Eppendorf Academic / other |
| Locations | 1 site (Hamburg) |
| Status | Recruiting |
| Started | March 1, 2019 |
| Main results expected | December 31, 2030 |
| Study ends | December 31, 2030 |
| Registry record updated | April 2, 2026 |
| Trial ID | NCT07508891 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (age 18 and over) who are hospitalized with a clinical diagnosis of acute heart failure—including de novo presentations, decompensated chronic heart failure, or cardiogenic shock—and who can provide written informed consent are ideal candidates.
✕Probably not a fit
Children, outpatients with acute heart failure, patients unable to give written consent, and individuals not admitted to the study hospital are not eligible and therefore are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This prospective, single-center observational cohort will enroll adults hospitalized with acute heart failure, including de novo cases, decompensated chronic heart failure, and all stages of cardiogenic shock. Researchers will collect functional clinical measures, radiological imaging with radiomics analysis, and circulating blood biomarkers, and will store biological samples in a biobank for future testing. The primary aim is to identify distinct patient phenotypes and combinations of biomarkers that improve individualized risk prediction. Results will generate hypotheses and candidate biomarkers to inform the design of future interventional trials.
Why it matters
Potential benefit: If successful, the findings could improve individualized risk prediction and help guide treatment decisions for patients hospitalized with acute heart failure.
How similar studies have gone: Previous cohort and biomarker studies have identified some prognostic markers in acute heart failure, but combining functional measures, radiomics, and prospective biobanking to define phenotypes is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Clinical diagnosis of acute heart failure, including all stages of cardiogenic shock, de novo heart failure as well as decompensated chronic heart failure. * Hospitalisation due to acute heart failure or new-onset acute heart failure during a hospitalisation de to a different cause. Out-patients with acute heart failure are not included. Exclusion Criteria: * Age \< 18 years * No written informed consent.
Where it's running
-
University Medical Center Hamburg-Eppendorf
Hamburg, Germany Recruiting
Study contacts
- Study coordinator: Benedikt Schrage, MD, PhD
- Email: b.schrage@uke.de
- Phone: +49 40 7410 0
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Registry of patients with acute cardiovascular diseases in Naples
This study looks at how patients with serious heart problems are treated and what happens to them while they are in the hospital and after they go home.
-
Factors Influencing Outcomes in ECMO and Impella Patients
This study tests whether metabolic and thyroid hormone changes help predict survival for adults on ECMO or Impella at a single Hungarian cardiac ICU.
-
Evaluating a noninvasive tissue sensor to detect cardiogenic shock earlier in heart patients
This pilot, noninvasive study tests whether the NIRSense wearable can help detect deterioration in adults with cardiogenic shock risk due to heart attack or heart failure.
-
Safety and Efficacy of an Extracorporeal Ventricular Assist System for Cardiogenic Shock
This study tests whether an extracorporeal ventricular assist device can safely provide short-term heart support and help patients with cardiogenic shock or trouble weaning from bypass.
-
Left Ventricular Support and Advanced Monitoring in AMI–Cardiogenic Shock: Immediate Impella Use and PAC/Monitoring vs Standard Care
In adults with heart attack-related cardiogenic shock, this trial tests whether using an Impella left ventricular assist device and/or protocolized pulmonary artery catheter monitoring improves survival compared with standard care.
-
CRP Apheresis for infarct-related cardiogenic shock
This study tests whether selectively removing C-reactive protein with apheresis, in addition to standard care, helps people with cardiogenic shock after a heart attack.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.